Accutar Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  Journal:  Bruton Tyrosine Kinase Degraders: Current Concepts. (Pubmed Central) -  Feb 14, 2025   
    While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance-both intrinsic and acquired-poses a significant challenge, often associated with BTK mutations like C481S...Agents such as NRX-0492, BGB-16673, NX-5948, NX-2127, HZ-Q1060, ABBV-101, and AC676 have shown significant BTK degradation in preclinical and early clinical trials...These BTK degraders have demonstrated favorable safety profiles, with manageable adverse events, and offer a novel therapeutic avenue for patients with BTKi-resistant malignancies. As clinical trials progress, these degraders hold the potential to significantly enhance treatment outcomes, offering a new frontier in personalized cancer therapy.
  • ||||||||||  Review, Journal:  PROTAC'ing the androgen receptor and other emerging therapeutics in prostate cancer. (Pubmed Central) -  Jul 18, 2024   
    PROTACs, DAARIs, and anitens represent novel and promising AR-targeting therapeutics that may become an important part of prostate cancer treatment in the future. Elucidating mechanisms of resistance, including ability of these agents to target full length AR, may yield further insights into maximal therapeutic efficacy aimed at silencing AR signaling.
  • ||||||||||  AC0682 / Accutar Biotech
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Apr 11, 2024   
    P1,  N=21, Terminated, 
    A phase 2 study will begin enrolling in early 2024. N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted.
  • ||||||||||  AC0682 / Accutar Biotech
    Trial completion date, Trial primary completion date:  A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=30, Active, not recruiting, 
    N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted. Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  AC0176 / Accutar Biotech
    Trial completion date, Trial termination:  A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Apr 1, 2024   
    P1,  N=28, Terminated, 
    Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024 Trial completion date: Nov 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
  • ||||||||||  AC0176 / Accutar Biotech
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=8, Terminated, 
    Abstract is embargoed at this time. Trial completion date: Jan 2026 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2023; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
  • ||||||||||  AC0682 / Accutar Biotech
    Trial completion date, Trial termination:  A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) -  Jan 24, 2024   
    P1,  N=6, Terminated, 
    Trial completion date: Jan 2026 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2023; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study Trial completion date: Dec 2024 --> Sep 2023 | Active, not recruiting --> Terminated; Voluntarily terminate the study since the sponsor's development strategy was adjusted.
  • ||||||||||  AC0176 / Accutar Biotech
    Enrollment closed, Enrollment change, Metastases:  A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Oct 26, 2023   
    P1,  N=8, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=150 --> 6 | Trial primary completion date: Jul 2023 --> Dec 2023 Recruiting --> Active, not recruiting | N=150 --> 8
  • ||||||||||  AC0682 / Accutar Biotech
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Oct 25, 2023   
    P1,  N=30, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=150 --> 8 Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
  • ||||||||||  AC0176 / Accutar Biotech
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Oct 23, 2023   
    P1,  N=36, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024
  • ||||||||||  AC0176 / Accutar Biotech
    Enrollment open, Metastases:  A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) -  Aug 25, 2023   
    P1,  N=150, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024 Not yet recruiting --> Recruiting